(B) T-V7 — Competitive Intelligence Brief

(B) T-V7 ((B) T-V7) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiarrhythmic. Area: Cardiovascular.

marketed Antiarrhythmic Potassium channels Cardiovascular Small molecule

Target snapshot

(B) T-V7 ((B) T-V7) — National Taiwan University Hospital. T-V7 is a medication used to treat atrial fibrillation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
(B) T-V7 TARGET	(B) T-V7	National Taiwan University Hospital	marketed	Antiarrhythmic	Potassium channels
Cordarone	AMIODARONE	Pfizer	marketed	Antiarrhythmic	sodium channels, potassium channels, calcium channels	1985-01-01
Minoxidil 5 % Topical Spray	Minoxidil 5 % Topical Spray	Sheikh Zayed Federal Postgraduate Medical Institute	marketed	Potassium channel opener / Topical hair growth stimulant	ATP-sensitive potassium channels (KATP)
amiodarone amiodarone	amiodarone amiodarone	National Heart, Lung, and Blood Institute (NHLBI)	marketed	Class III antiarrhythmic agent	Potassium channels (hERG), sodium channels, beta-adrenergic receptors, calcium channels
metformin/glimepiride combination	metformin/glimepiride combination	Laboratorios Silanes S.A. de C.V.	marketed	Biguanide/Sulfonylurea combination	AMP-activated protein kinase (AMPK) pathway; ATP-sensitive potassium channels (KATP)
metformin+ gliclazide	metformin+ gliclazide	GlaxoSmithKline	marketed	Antidiabetic combination (biguanide + sulfonylurea)	Metformin: mitochondrial glycerophosphate dehydrogenase; Gliclazide: ATP-sensitive potassium channels on pancreatic beta cells
minoxidil + finasteride	minoxidil + finasteride	Beijing Dayspring Pharmaceutical Technology Co., Ltd	marketed	Combination antialopecia agent	Potassium channels (minoxidil); 5-alpha reductase type II (finasteride)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiarrhythmic class)

1. Pfizer · 3 drugs in this class
2. National Taiwan University Hospital · 2 drugs in this class
3. Boehringer Ingelheim · 1 drug in this class
4. Cliniques universitaires Saint-Luc- Université Catholique de Louvain · 1 drug in this class
5. Eli Lilly · 1 drug in this class
6. MTI Medical Private Limited, Pakistan · 1 drug in this class
7. Technical University of Munich · 1 drug in this class
8. · 1 drug in this class
9. Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class
10. Ain Shams University · 1 drug in this class